Genomic alterations in DLC1 contribute to drug sensitivity and confer growth advantage upon activation of RHO-ROCK signalling, rendering tumour cells more susceptible to ROCK-inhibitors (e.g., Y-27632). This evidence concerns the gene DLC1 and neoplasm.